Weekly Digest – January 2025 Weekly Digest – January 2025 20 Jan 2025: YL201 received another Breakthrough Therapy Designation for the treatment of R/M Nasopharyngeal Carcinoma MediLink receives CDE Breakthrough Therapy Designation for YL201 for recurrent/metastatic nasopharyngeal carcinoma following prior […]
Weekly Digest – January 2025 Weekly Digest – January 2025 17 Jan 2025: Datroway (Datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR+, HER2- Breast Cancer Datroway is approved by FDA for metastatic HR-positive, HER2-negative breast […]
Weekly Digest – January 2025 Weekly Digest – January 2025 21 Jan 2025: ArriVent BioPharma enters exclusive license with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers ArriVent BioPharma entered to exclusive license agreement […]
Weekly Digest – January 2025 Weekly Digest – January 2025 22 Jan 2025: Vincerx Pharma enters at-the-market equity offering deal Vincerx partnered with H.C. Wainwright & Co. for a $30 million at-the-market equity offering Recently, it terminated sales agreement with […]
Weekly Digest – January 2025 Weekly Digest – January 2025 20 Jan 2025: GI Innovation, LaNova Medicines sign MOU to develop combination therapy for pancreatic cancer GI Innovation & LaNova signed MOU to develop a pancreatic cancer combination therapy with […]
Weekly Digest – January 2025 Weekly Digest – January 2025 16 Jan 2025: Innovent receives NMPA Breakthrough Therapy Designation for IBI343 (anti-CLDN18.2 ADC) as monotherapy for advanced Pancreatic Cancer Innovent Biologics received Breakthrough Therapy Designation (BTD) from the NMPA for […]
Weekly Digest – January 2025 Weekly Digest – January 2025 13 Jan 2025: Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated Non-Small Cell Lung Cancer Datopotamab deruxtecan (Dato-DXd) received FDA Priority Review for […]
Weekly Digest – January 2025 Weekly Digest – January 2025 10 Jan 2025: Mersana Therapeutics announces additional FDA Fast Track Designation granted to Emiltatug Ledadotin (XMT-1660) XMT-1660 (Emi-Le) received a new Fast Track designation for advanced or metastatic HER2-low or HER2-negative […]
Weekly Digest – January 2025 Weekly Digest – January 2025 15 Jan 2025: Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference Celltrion unveiled its strategic roadmap for innovative drug development, […]
Weekly Digest – January 2025 Weekly Digest – January 2025 15 Jan 2025: Zai Lab announces positive topline results for TIVDAK in the China subpopulation of the global phase 3 innovaTV 301 trial in patients with recurrent or metastatic Cervical […]
